BACKGROUND: Oncolytic virotherapeutics is a promising platform for cancer treatment but the product class has yet been successful. The key to success is integration of bidirectional translational research to rapidly address issues encountered in the laboratory and the clinics. OBJECTIVE: We highlight the hurdles identified for the targeted oncolytic virotherapy approach, specifically those identified in clinical trials with wild-type viruses and first-generation targeted agents. We also analyze the translational research and development that has been applied to overcome these hurdles, including virus engineering and design improvements for next-generation virotherapeutics. RESULTS/ CONCLUSION: The iterative loop between the clinic and the lab can function as a major driving force to optimize products from this platform.
BACKGROUND: Oncolytic virotherapeutics is a promising platform for cancer treatment but the product class has yet been successful. The key to success is integration of bidirectional translational research to rapidly address issues encountered in the laboratory and the clinics. OBJECTIVE: We highlight the hurdles identified for the targeted oncolytic virotherapy approach, specifically those identified in clinical trials with wild-type viruses and first-generation targeted agents. We also analyze the translational research and development that has been applied to overcome these hurdles, including virus engineering and design improvements for next-generation virotherapeutics. RESULTS/ CONCLUSION: The iterative loop between the clinic and the lab can function as a major driving force to optimize products from this platform.
Authors: Jean-Simon Diallo; Fabrice Le Boeuf; Frances Lai; Julie Cox; Markus Vaha-Koskela; Hesham Abdelbary; Heather MacTavish; Katherine Waite; Theresa Falls; Jenny Wang; Ryan Brown; Jan E Blanchard; Eric D Brown; David H Kirn; John Hiscott; Harry Atkins; Brian D Lichty; John C Bell Journal: Mol Ther Date: 2010-04-13 Impact factor: 11.454
Authors: Brent J Passer; Tooba Cheema; Bingsen Zhou; Hiroaki Wakimoto; Cecile Zaupa; Mani Razmjoo; Jason Sarte; Shulin Wu; Chin-lee Wu; James W Noah; Qianjun Li; John K Buolamwini; Yun Yen; Samuel D Rabkin; Robert L Martuza Journal: Cancer Res Date: 2010-04-27 Impact factor: 12.701
Authors: Kelley A Parato; Caroline J Breitbach; Fabrice Le Boeuf; Jiahu Wang; Chris Storbeck; Carolina Ilkow; Jean-Simon Diallo; Theresa Falls; Joseph Burns; Vanessa Garcia; Femina Kanji; Laura Evgin; Kang Hu; Francois Paradis; Shane Knowles; Tae-Ho Hwang; Barbara C Vanderhyden; Rebecca Auer; David H Kirn; John C Bell Journal: Mol Ther Date: 2011-12-20 Impact factor: 11.454